General Biotech

ADLM 2025 was held in Chicago, IL, USA, from July 27-31. The Association for Diagnostics & Laboratory Medicine event hosted global leaders in clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other areas of breaking science in laboratory me

Benchmark Positive Antibodies ensure reliable validation. Biointron explains their role in confirming assay accuracy and building trust in experimental results.

FcRn is critical for IgG recycling and half-life extension. Biointron explores its biology and applications in designing durable therapeutic antibodies.

Clear intellectual property policies foster biotech growth. Biointron shows how no-royalty models encourage innovation, collaboration, and therapeutic progress.

Phage display technology revolutionizes antibody discovery. Biointron applies this platform to identify high-affinity binders and accelerate therapeutic innovation.

In vivo and in vitro models each shape antibody discovery differently. Biointron compares their roles in research and development to guide better therapeutic strategies.

Microfluidic technology is transforming biotechnology. Biointron shows how microfluidics enhance antibody research with precision, speed, and innovative applications.

Dilution buffers ensure reliable antibody research. Biointron explains their roles in maintaining stability, accuracy, and reproducibility in experimental workflows.

ADC biosimilars and biobetters differ in design and benefit. Biointron explains distinctions and how innovation improves safety, efficacy, and patient outcomes.

ADCs enhance in vivo research precision. Biointron explores how targeted payload delivery improves study accuracy and supports next-generation therapeutic design.

Research-use-only biologics support early discovery. Biointron explains how RUO materials empower preclinical antibody development and accelerate translational progress.

Muronomab (Orthoclone OKT3) made history as the first FDA-approved monoclonal antibody. Biointron reviews its impact on immunotherapy and antibody drug development.